{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:50:42Z","timestamp":1780642242721,"version":"3.54.1"},"reference-count":47,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":2867,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2005,5]]},"abstract":"<jats:p>Exenatide is an incretin mimetic with potential glucoregulatory activity in type 2 diabetes. This randomized, single\u2010blind, placebo\u2010controlled 6\u2010way crossover study assessed exenatide's effect on acetaminophen pharmacokinetics. Of 40 randomized healthy subjects, 39 completed the study. On the placebo day, acetaminophen (1000 mg) was ingested and placebo injected subcutaneously at 0 hours. On exenatide days, acetaminophen was ingested at \u22121, 0, +1, +2, and +4 hours, relative to the 10 \u03bcg exenatide injected subcutaneously at 0 hours. With exenatide injection, mean plasma acetaminophen AUC<jats:sub><jats:italic>0\u201312 h<\/jats:italic><\/jats:sub> values were reduced by 11% to 24% (vs placebo). Peak plasma acetaminophen concentrations were similar for the \u22121\u2010hour and placebo groups and reduced by 37% to 56% at other times. The most frequent adverse events were generally mild to moderate nausea and vomiting. Exenatide treatment concurrent with or preceding acetaminophen ingestion slowed acetaminophen absorption but had minimal effect on the extent of absorption.<\/jats:p>","DOI":"10.1177\/0091270004274432","type":"journal-article","created":{"date-parts":[[2005,4,14]],"date-time":"2005-04-14T19:13:30Z","timestamp":1113506010000},"page":"570-577","source":"Crossref","is-referenced-by-count":69,"title":["Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin\u20104) in Healthy Subjects"],"prefix":"10.1002","volume":"45","author":[{"given":"Erich","family":"Blase","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u2010ye","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Wintle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fineman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.44.11.1249"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.3.360"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-4-199908170-00008"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021545"},{"key":"e_1_2_5_7_2","first-page":"401","article-title":"Pharmacology of exenatide (synthetic exendin\u20104) for the treatment of type 2 diabetes","volume":"4","author":"Nielsen LL","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2001.22519"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2003.10.028"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.3.8337"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.328"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401145"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.281.1.E155"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07952-7"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.48.5.1026"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.6.7490"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.8.2370"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01316798"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1999.277.3.R910"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655201750065906"},{"key":"e_1_2_5_21_2","first-page":"A403","article-title":"Exendin\u20104 potently stimulates gastric emptying in rats [abstract]","volume":"47","author":"Jodka C","year":"1998","journal-title":"Diabetes"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00264.x"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03409.x"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00614304"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1992.tb04104.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003257229"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655200750023930"},{"key":"e_1_2_5_28_2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1001\/jama.1997.03540350075038","article-title":"Declaration of Helsinki: recommendations guiding medical physicians in biomedical research involving human subjects","volume":"277","year":"1997","journal-title":"JAMA."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-198207020-00001"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400362"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/48.4.1035"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00658.x"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70080-5"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199602)13:2<112::AID-DIA37>3.0.CO;2-H"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00186645"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265086"},{"key":"e_1_2_5_37_2","first-page":"29","article-title":"Gastric emptying in patients with insulin\u2010requiring diabetes mellitus","volume":"82","author":"Keshavarzian A","year":"1987","journal-title":"Am J Gastroenterol."},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1159\/000171237"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.3.413"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.1.23"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-0690(18)30062-4"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199427060-00004"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004123221502"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1022528414264"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01296773"},{"key":"e_1_2_5_46_2","first-page":"223","article-title":"Update: pharmaceuticals and gastric emptying","volume":"85","author":"Chaudhuri TK","year":"1990","journal-title":"Am J Gastroenterol."},{"key":"e_1_2_5_47_2","first-page":"A65","article-title":"Effect of exenatide on digoxin pharmacokinetics","volume":"31","author":"Soon D","year":"2004","journal-title":"Clin Exp Pharmacol Physiol."},{"key":"e_1_2_5_48_2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a range of subcutaneous exenatide in patients with type 2 diabetes mellitus","volume":"15","author":"Kolterman OG","year":"2005","journal-title":"Am J Health-Sys Pharmacy."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270004274432","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270004274432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T08:59:18Z","timestamp":1697446758000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270004274432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1177\/0091270004274432"],"URL":"https:\/\/doi.org\/10.1177\/0091270004274432","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}